BACKGROUND: Chronic intestinal pseudo-obstruction (CIPO) is a rare condition due to severe impairment of gut motility responsible for recurrent subocclusive episodes. Although neuromuscular-glial-ICC abnormalities represent the main pathogenetic mechanism, the pathophysiology of CIPO remains poorly understood. Intestinal epithelial and vascular endothelial barrier (IEVB) abnormalities can contribute to neuroepithelial changes by allowing passage of harmful substances. METHODS: To test retrospectively whether IEVB defects occur in patients with CIPO, we measured the jejunal protein expression of the major tight junction (TJ) components. CIPO patients were subdivided according to gut neuromuscular histopathology: apparently normal (AN); with inflammation (INF); or with degenerative alterations (DEG). The presence of occludin/claudin oligomers (index of TJ assembly), the amount of occludin, claudin-4, and zonula occludens-1 (ZO-1), and the expression of vasoactive intestinal polypeptide (VIP) and glial fibrillary acidic protein (GFAP) immunoreactivities were evaluated on jejunal full-thickness biopsies using Western blot. KEY RESULTS: Oligomers were absent in the 73% of CIPO. Total occludin decreased in CIPO with AN and INF changes. Claudin-4 was upregulated in CIPO with INF and DEG features. ZO-1 and VIP expression decreased selectively in DEG group. GFAP increased in CIPO regardless the histopathological phenotype. CONCLUSIONS & INFERENCES: The absence of oligomers demonstrated in our study suggests that IEBV is altered in CIPO. The mechanism leading to oligomerization is occludin-dependent in AN and INF, whereas is ZO-1-dependent in DEG. Our study provides support to IEVB abnormalities contributing to CIPO clinical and histopathological features.
BACKGROUND:Chronic intestinal pseudo-obstruction (CIPO) is a rare condition due to severe impairment of gut motility responsible for recurrent subocclusive episodes. Although neuromuscular-glial-ICC abnormalities represent the main pathogenetic mechanism, the pathophysiology of CIPO remains poorly understood. Intestinal epithelial and vascular endothelial barrier (IEVB) abnormalities can contribute to neuroepithelial changes by allowing passage of harmful substances. METHODS: To test retrospectively whether IEVB defects occur in patients with CIPO, we measured the jejunal protein expression of the major tight junction (TJ) components. CIPOpatients were subdivided according to gut neuromuscular histopathology: apparently normal (AN); with inflammation (INF); or with degenerative alterations (DEG). The presence of occludin/claudin oligomers (index of TJ assembly), the amount of occludin, claudin-4, and zonula occludens-1 (ZO-1), and the expression of vasoactive intestinal polypeptide (VIP) and glial fibrillary acidic protein (GFAP) immunoreactivities were evaluated on jejunal full-thickness biopsies using Western blot. KEY RESULTS: Oligomers were absent in the 73% of CIPO. Total occludin decreased in CIPO with AN and INF changes. Claudin-4 was upregulated in CIPO with INF and DEG features. ZO-1 and VIP expression decreased selectively in DEG group. GFAP increased in CIPO regardless the histopathological phenotype. CONCLUSIONS & INFERENCES: The absence of oligomers demonstrated in our study suggests that IEBV is altered in CIPO. The mechanism leading to oligomerization is occludin-dependent in AN and INF, whereas is ZO-1-dependent in DEG. Our study provides support to IEVB abnormalities contributing to CIPO clinical and histopathological features.
Authors: Roberto De Giorgio; Rosanna F Cogliandro; Giovanni Barbara; Roberto Corinaldesi; Vincenzo Stanghellini Journal: Gastroenterol Clin North Am Date: 2011-12 Impact factor: 3.806
Authors: Charles H Knowles; Roberto De Giorgio; Raj P Kapur; Elisabeth Bruder; Gianrico Farrugia; Karel Geboes; Greger Lindberg; Joanne E Martin; William A Meier-Ruge; Peter J Milla; Virpi V Smith; Jean Marie Vandervinden; Béla Veress; Thilo Wedel Journal: Gut Date: 2010-07 Impact factor: 23.059
Authors: Sam Horng; Anthony Therattil; Sarah Moyon; Alexandra Gordon; Karla Kim; Azeb Tadesse Argaw; Yuko Hara; John N Mariani; Setsu Sawai; Per Flodby; Edward D Crandall; Zea Borok; Michael V Sofroniew; Candice Chapouly; Gareth R John Journal: J Clin Invest Date: 2017-07-24 Impact factor: 14.808
Authors: C Malagelada; T B Karunaratne; A Accarino; R F Cogliandro; S Landolfi; A Gori; E Boschetti; J R Malagelada; V Stanghellini; F Azpiroz; R De Giorgio Journal: Neurogastroenterol Motil Date: 2017-09-22 Impact factor: 3.598
Authors: V S Conlin; X Wu; C Nguyen; C Dai; B A Vallance; A M J Buchan; L Boyer; K Jacobson Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-08-06 Impact factor: 4.052
Authors: Tor C Savidge; Paul Newman; Charalabos Pothoulakis; Anne Ruhl; Michel Neunlist; Arnaud Bourreille; Roger Hurst; Michael V Sofroniew Journal: Gastroenterology Date: 2007-02-01 Impact factor: 22.682